AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Selling, General and Administrative Expenses

Last Annual Value

230.12M

3-Year CAGR

131%

5-Year CAGR

122%

10-Year CAGR

60%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Selling, General and Administrative Expenses

SPRY · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
230.12M
69.5%117.9%N/A 
15.89M
-10.9%-1.5%-8.7%
SVRA logo
Savara Inc.
NASDAQ:SVRA
42.06M
39.0%27.8%31.0%
119.98M
33.4%20.9%31.2%
15.76M
72.4%-1.1%N/A
91.14M
91.8%33.1%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
51.78M
4.9%42.4%N/A
29.83M
19.6%39.5%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
18.37M
14.7%18.4%12.8%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07